Vilimed - Company finances
|
EUR
|
2019
From: 2019-01-04
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|
|
Financial data
|
|||||||
| Sales revenue | 11,809 | 11,134 | 33,148 | 106,190 | 126,520 | 506,732 | 719,675 |
| Profit before tax | -18,012 | -44,325 | -34,224 | 12,874 | -91,028 | -22,893 | 16,727 |
| Net profit | -18,012 | -44,325 | -34,224 | 12,874 | -91,223 | -24,334 | 15,566 |
| Equity | -15,512 | -59,836 | -94,060 | 239,239 | 148,015 | 123,681 | 139,247 |
| Liabilities | 20,529 | 70,891 | 111,933 | 83,999 | 17,518 | 62,218 | 80,024 |
| Non-current assets | 0 | 0 | 0 | 905 | 586 | 5,835 | 5,677 |
| Current assets | 5,017 | 11,014 | 21,118 | 325,554 | 164,729 | 373,905 | 307,628 |
| Total assets | 5,017 | 11,014 | 21,118 | 326,459 | 165,315 | 379,740 | 313,305 |
|
Taxes paid
|
|||||||
| STI taxes | - | - | - | - | 26,885 | 31,726 | 40,807 |
| Social insurance contributions | - | - | - | - | 35,446 | 52,985 | 69,666 |
|
Financial indicators
|
|||||||
| Revenue change y/y | - | -5.7% | +197.7% | +220.4% | +19.1% | +300.5% | +42.0% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -359.0% | -402.4% | -162.1% | 3.9% | -55.2% | -6.4% | 5.0% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | - | 5.4% | -61.6% | -19.7% | 11.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -152.5% | -398.1% | -103.2% | 12.1% | -72.1% | -4.8% | 2.2% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -152.5% | -398.1% | -103.2% | 12.1% | -71.9% | -4.5% | 2.3% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | 0.4 | 0.1 | 0.5 | 0.6 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 5,905 | 2,784 | 7,800 | 23,598 | 16,503 | 49,842 | 65,425 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Vilimed - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2024-07-24 | 2024-08-04 | 1.17 |
| 2024-06-18 | 2024-06-26 | 256.94 |
| 2024-05-16 | 2024-05-21 | 208.00 |
Vilimed - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Vilimed, UAB (code 304982381) is a Private Limited Liability Company engaged in research and development in medical sciences. In 2025, the company increased revenue to €719.7K, up 42.0% year on year and 468.8% over two years. Net profit turned positive at €15.6K, compared with a loss of €24.3K in 2024 and €91.2K in 2023, while the profit margin improved to 2.2% from -4.8% and -72.1% in the prior two years. The balance sheet remained moderately leveraged, with total assets of €313.3K, equity of €139.2K and liabilities of €80.0K at the end of 2025. The equity ratio stood at 44.4%, debt-to-equity at 0.57, and asset turnover at 2.30x. Profitability ratios were also positive, with ROE at 11.2% and ROA at 5.0%. Revenue per employee reached €65.4K and profit per employee €1.4K, indicating improved operating performance after the loss-making phase in 2023–2024.